Original Contribution | Published:


Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study

The American Journal of Gastroenterology volume 112, pages 15381544 (2017) | Download Citation

  • A Corrigendum to this article was published on 19 December 2017



Management of eosinophilic esophagitis (EoE) requires repeated endoscopic mucosal sampling to assess disease activity. A less invasive and expensive means of monitoring of EoE is required. The objective of this study was to assess the accuracy, safety, and tolerability of the cytosponge compared to endoscopy and biopsy for histologic assessment of EoE.


In this prospective two-center cross-sectional study, patients with known EoE underwent cytosponge sampling followed by endoscopy and biopsy. Sample adequacy and eosinophil counts (eos/HPF) were determined for both cytosponge and endoscopic samples. The cytosponge was assessed for diagnostic accuracy, safety, and patient preference as compared to endoscopy.


Six patients (7%) failed to swallow the sponge. One hundred and five procedures were successfully performed in 80 patients (66% male, 100% white, 19% stricture). The cytosponge sample was adequate in 102 and the biopsy in 104; 101 procedures had adequate samples by both techniques. Fifty-seven biopsies were graded as active EoE with ≥15 eos/HPF as the gold standard. Eosinophil counts highly correlated between the biopsy and cytosponge (r=0.78, P<0.0001). Using a cutoff of ≤15 eos/HPF for inactive disease, the sensitivity and specificity of the cytosponge was 75% and 86%, respectively. Six patients had active EoE on cytosponge not found on biopsy. For biopsies with inactive EoE, the cytosponge identified 38/44. No complications occurred, and cytosponge endoscopic abrasion scores were low (0.34/4). Patients preferred cytosponge to endoscopy with higher rating scores (7.27 vs. 6.11, P=0.002).


Compared to endoscopy with biopsy, cytosponge provided a minimally invasive, safe, well tolerated, and accurate method to assess EoE histologic activity. (ClinicalTrial.gov number NCT01585103).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20.e6.

  2. 2.

    , , et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology 2016;150:581–90.e4.

  3. 3.

    , , et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 2014;79:577–85.e4.

  4. 4.

    , , . Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol 2016;50:134–40.

  5. 5.

    , , et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013;145:1230–6.

  6. 6.

    , , et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20.e6.

  7. 7.

    , , et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013;108:679–92.

  8. 8.

    , , et al. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol 2015;110:626–32.

  9. 9.

    , , et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013;131:797–804.

  10. 10.

    , , et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012;142:1451–9.e1.

  11. 11.

    , . Non- and semi-invasive methods of monitoring eosinophilic esophagitis. Dig Dis 2014;32:102–6.

  12. 12.

    , , et al. Utility of a noninvasive serum biomarker panel for diagnosis and monitoring of eosinophilic esophagitis: a prospective study. Am J Gastroenterol 2015;110:821–7.

  13. 13.

    , , et al. Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis. Allergy Asthma Proc 2012;33:519–24.

  14. 14.

    , , et al. Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr 2011;53:651–8.

  15. 15.

    , , et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 2013;144:62–73.e6.

  16. 16.

    , , et al. Non-endoscopic screening biomarkers for Barrett’s oesophagus: from microarray analysis to the clinic. Gut 2009;58:1451–9.

  17. 17.

    , , . Developing a nonendoscopic screening test for Barrett’s esophagus. Biomark Med 2011;5:397–404.

  18. 18.

    , , et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med 2015;12:e1001780.

  19. 19.

    , , et al. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. Histopathology 2016;70:203–10.

  20. 20.

    , , et al. Accuracy, safety, and tolerability of tissue collection by cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2015;13:77–83 e2.

  21. 21.

    , , . Impact of event scale: a measure of subjective stress. Psychosom Med 1979;41:209–18.

  22. 22.

    , , et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62:489–95.

  23. 23.

    , , et al. Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis. J Gastroenterol Hepatol Res 2015;4:1780–7.

  24. 24.

    . Pathology of eosinophilic esophagitis: what the clinician needs to know. Am J Gastroenterol 2009;104:485–90.

  25. 25.

    , , et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313–9.

  26. 26.

    , , et al. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 2015;28:383–90.

  27. 27.

    , , et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc 2012;75:954–61.

  28. 28.

    , , et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 2013;62:1395–405.

  29. 29.

    , , et al. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. Gastrointest Endosc 2016;83:299–306 e1.

  30. 30.

    , , et al. Ultrathin unsedated transnasal gastroscopy in monitoring eosinophilic esophagitis. J Gastroenterol Hepatol 2016;31:590–4.

  31. 31.

    , , et al. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1328–36.

  32. 32.

    , , et al. Eosinophil quantitated urine kinetic: a novel assay for assessment of eosinophilic esophagitis. Ann Allergy Asthma Immunol 2016;116:435–9.

Download references

Author information


  1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

    • David A Katzka
    • , Thomas C Smyrk
    • , Jeffrey A Alexander
    • , Debra M Geno
    • , RoseMary A Beitia
    • , Audrey O Chang
    • , Nicholas J Shaheen
    • , Rebecca C Fitzgerald
    •  & Evan S Dellon


  1. Search for David A Katzka in:

  2. Search for Thomas C Smyrk in:

  3. Search for Jeffrey A Alexander in:

  4. Search for Debra M Geno in:

  5. Search for RoseMary A Beitia in:

  6. Search for Audrey O Chang in:

  7. Search for Nicholas J Shaheen in:

  8. Search for Rebecca C Fitzgerald in:

  9. Search for Evan S Dellon in:

Competing interests

Guarantor of the article:  .

Specific author contributions: D.A.K.: study design, data collection and analysis, and writing of the manuscript. T.C.S.: study design, data collection and analysis, and writing of the manuscript. D.M.G.: study design, data collection, and proofing of the manuscript. R.A.B.: data collection and proofing of the manuscript. A.U.C.: data interpretation and proofing of the manuscript. J.A.A.: study design, data collection, and proofing of the manuscript. R.C.F.: study design, writing, and proofing of the manuscript. E.S.D.: study design, data collection and analysis, and writing of the manuscript.

Financial support: This study was funded in part by a grant from the CURED Foundation (E.S.D.), AGA Covidien Award (D.A.K.), and NIH T35 DK007386 (A.O.C.).

Potential competing interests: E.S.D.: No potential competing interests related to this study. Consultant for Adare, Alivio, Banner, Celgene/Receptos, Regeneron, and Shire. Research funding from Meritage, Miraca, Nutricia, Celgene/Receptos, Regeneron, and Shire. Educational grant from Banner. D.A.K.: Consultant for Adare and Shire; research funding from AGA-Covidien Grant. J.A.A.: Consultant for Meritage Pharmacia, stock ownership Meritage Pharmacia. R.C.F.: Inventor on patents for the cytosponge. N.J.S.: Medtronic, CSA Medical, C2 Therapeutics, Boston Scientific, CDx Medical, and EndosStim. T.C.S., D.M.G., R.A.B., and A.U.C. declare no conflict of interest.

Corresponding author

Correspondence to David A Katzka.

Supplementary information

About this article

Publication history






SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/ajg

Further reading